Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 01, 2018 09:26 ET | Source: Aptose Biosciences, Inc.

Aptose to Present New CG-806 Data at the 2018 ASH Annual Meeting

SAN DIEGO and TORONTO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
October 23, 2018 07:05 ET | Source: Aptose Biosciences, Inc.

Aptose to Release Third Quarter Ended September 30, 2018 Financial Results on November 6, 2018

Conference Call to Be Held Wednesday, November 7, 2018 SAN DIEGO and TORONTO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing...
September 27, 2018 07:05 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences and CrystalGenomics Announce Issuance of European Patent for CG-806

SAN DIEGO, TORONTO and SEOUL, South Korea, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that the European Patent...
September 25, 2018 07:05 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at Upcoming Investor Conferences in October 2018

SAN DIEGO, Calif. and TORONTO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
August 29, 2018 07:05 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at Upcoming Investor Conferences in September 2018

SAN DIEGO and TORONTO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
August 15, 2018 07:05 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Appointment of Carol Ashe to Board of Directors

SAN DIEGO and TORONTO, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
August 07, 2018 16:18 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the Second Quarter Ended June 30, 2018

SAN DIEGO and TORONTO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
August 02, 2018 07:05 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences to Present at Canaccord Genuity 38th Annual Growth Conference

SAN DIEGO and TORONTO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
July 31, 2018 08:00 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at the 2018 Global Congress on Oncology and Cancer

SAN DIEGO and TORONTO, July 31, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
July 24, 2018 07:05 ET | Source: Aptose Biosciences, Inc.

Aptose To Release Second Quarter Ended June 30, 2018 Financial Results and Hold Conference Call on August 7, 2018

SAN DIEGO and TORONTO, July 24, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the...